Duality Advisers, LP Arcus Biosciences, Inc. Transaction History

Duality Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$16.97 - $22.03 $492,978 - $639,971	29,050 New	29,050 $590,000
Q4 2022 Feb 07, 2023	BUY	$19.7 - $35.71 $1.11 Million - $2.02 Million	56,589 Added 228.17%	81,390 $1.68 Million
Q3 2022 Nov 03, 2022	BUY	$23.23 - $30.07 $576,127 - $745,766	24,801 New	24,801 $649,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.